CorMedix Inc. Q2 2026 Earnings Call Summary

CorMedix Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, August 14, 2026 at 4:04 AM GMT+3 3 min read

• CRMD -7.37%

Strategic Execution and Commercial Expansion

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Secured a multi-year commercial supply agreement with the final remaining top-5 large dialysis organization (LDO), achieving full coverage of the leading U.S. dialysis providers.

• Maintained stable DefenCath utilization through the initial post-TDAPA reimbursement transition, with July order volumes aligning with management's internal forecasts.

• Implemented contract amendments with major customers to provide pricing and volume visibility through year-end 2026 and into 2027, aimed at ensuring patient therapy continuity.

• Advanced the REZZAYO pipeline following positive Phase III ReSPECT data, which demonstrated non-inferiority to standard antifungal regimens in preventing invasive fungal disease.

• Leveraged the Melinta portfolio acquisition to drive significant year-over-year revenue growth and establish a diversified, cash-generative business model.

• Focused internal resources on Medicare Advantage contracting, viewing it as a critical long-term growth lever despite lengthy negotiation cycles.

• Utilized a growing body of real-world evidence to validate DefenCath's clinical value proposition, specifically regarding reductions in hospitalizations and tPA usage.

Pipeline Milestones and Financial Outlook

• Anticipate submission of the REZZAYO sNDA for prophylaxis in Q3 2026, with potential FDA action expected in the first half of 2027.

• Raised full-year 2026 adjusted EBITDA guidance to $125-$140 million, reflecting disciplined capital allocation and operational efficiencies.

• Planning a strategic commercial scale-up for REZZAYO in the second half of 2026, including 15 to 20 new positions to prepare for a potential 2027 launch.

• Expect to complete the Phase III TPN study in 2028, supported by protocol amendments designed to accelerate patient enrollment.

• Monitoring the final ESRD rule expected in November 2026 to adjust commercial strategies based on the finalized Medicare reimbursement framework.

Operational Adjustments and Risk Factors

• Recorded a $4.2 million G&A expense reduction in Q2 2026 due to insurance reimbursement for legal fees related to ongoing securities litigation.

• Acknowledged expected attrition among smaller dialysis providers following the TDAPA expiration, while larger accounts remain stable.

• Noted that 2026 guidance excludes potential contributions from Medicare Advantage contracts due to the uncertainty of timing.

• Highlighted that ownership of the REZZAYO U.S. NDA will transfer from Mundipharma to CorMedix only upon FDA approval of the prophylaxis indication.

Q&A Session Highlights

Impact of new LDO agreement on 2027 revenue and pilot scope

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

• Management stated the new LDO pilot involves a couple hundred clinics and is currently reflected within existing 2026 guidance.

• Specific 2027 guidance will not be provided until late 2026 or early 2027, pending visibility into pilot adoption and Medicare Advantage progress.

Volume growth levers in the post-TDAPA environment

• Management identified two primary levers for future volume growth: meaningful adoption by the new LDO and successful Medicare Advantage contracting.

• Current volumes are described as stabilized with large players, offsetting anticipated attrition among smaller facilities.

REZZAYO prophylaxis labeling and market research feedback

• Management noted that robust market research is pending the publication of full Phase III data in Q4 2026.

• The final scope of the label for prophylaxis will be determined during the FDA review process following the Q3 sNDA submission.

SG&A run rate and sales infrastructure adjustments

• Management confirmed no reductions were made to the DefenCath sales and marketing infrastructure despite the reimbursement transition.

• The Q2 G&A expense was 'artificially low' due to a $4.2 million litigation-related insurance credit, $2.7 million of which related to prior periods.